Candel Therapeutics, Inc. (CADL)

NGM – Цена в реальном времени. Валюта: USD

8.72

-0.13 (-1.47%)

При закрытии: May 12, 2026, 4:00 PM EDT

04.05.2026

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel's management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company's extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plenary presentation of these data by Mark G. Garzatto, M.D., Professor of Urology at Oregon Health & Science University and the Portland VA Medical Center, at the American Urological Association (AUA) 2026 Annual Meeting.

01.05.2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients with cancer, today announced that on April 30, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 29,400 shares of the Company's common stock, with a per share exercise price of $6.18.

29.04.2026

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. Under the deal, EVERSANA will deliver an integrated range of services covering data and analytics, medical affairs, market access, and field operations.

29.04.2026

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026

21.04.2026

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene.

20.04.2026

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics (NASDAQ:CADL) ripped higher Monday after a new bullish analyst initiation reminded the market that, in clinical-stage land, narrative can move faster than fundamentals. Here's what you should know.

02.04.2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company's common stock, with a per share exercise price of $4.90.

Видео

No Data

There is no data to display

Пресс-релизы

01.05.2026

Candel Therapeutics, Inc. (CADL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Search stocks

Candel Therapeutics, Inc. (CADL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors